FY2018 EPS Estimates for Agile Therapeutics, Inc. Reduced by Analyst (AGRX)

Agile Therapeutics, Inc. (NASDAQ:AGRX) – Stock analysts at William Blair dropped their FY2018 EPS estimates for Agile Therapeutics in a research report issued on Wednesday. William Blair analyst T. Lugo now forecasts that the specialty pharmaceutical company will post earnings per share of ($0.59) for the year, down from their previous estimate of ($0.09). William Blair also issued estimates for Agile Therapeutics’ FY2019 earnings at $0.31 EPS.

Agile Therapeutics (NASDAQ:AGRX) last released its quarterly earnings results on Friday, July 28th. The specialty pharmaceutical company reported ($0.26) EPS for the quarter, beating analysts’ consensus estimates of ($0.28) by $0.02. During the same period in the previous year, the business earned ($0.29) earnings per share.

COPYRIGHT VIOLATION WARNING: “FY2018 EPS Estimates for Agile Therapeutics, Inc. Reduced by Analyst (AGRX)” was posted by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are viewing this piece of content on another publication, it was illegally copied and reposted in violation of United States & international copyright laws. The original version of this piece of content can be read at https://www.dispatchtribunal.com/2017/10/13/fy2018-eps-estimates-for-agile-therapeutics-inc-reduced-by-analyst-agrx.html.

A number of other research analysts have also recently commented on AGRX. HC Wainwright reiterated a “buy” rating and issued a $10.00 price objective on shares of Agile Therapeutics in a report on Monday, October 2nd. Noble Financial reiterated a “buy” rating on shares of Agile Therapeutics in a report on Sunday, July 30th. ValuEngine cut Agile Therapeutics from a “sell” rating to a “strong sell” rating in a report on Friday, September 1st. Janney Montgomery Scott reiterated a “buy” rating and issued a $13.00 price objective (down from $15.00) on shares of Agile Therapeutics in a report on Thursday, August 24th. Finally, Cantor Fitzgerald reiterated an “overweight” rating and issued a $8.00 price objective on shares of Agile Therapeutics in a report on Thursday, September 21st. One investment analyst has rated the stock with a sell rating and six have given a buy rating to the company. The stock has a consensus rating of “Buy” and a consensus target price of $10.20.

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Franklin Resources Inc. lifted its holdings in Agile Therapeutics by 39.2% in the second quarter. Franklin Resources Inc. now owns 2,772,200 shares of the specialty pharmaceutical company’s stock valued at $10,396,000 after acquiring an additional 780,578 shares during the last quarter. Royce & Associates LP lifted its holdings in Agile Therapeutics by 1.1% in the second quarter. Royce & Associates LP now owns 998,582 shares of the specialty pharmaceutical company’s stock valued at $3,745,000 after acquiring an additional 11,000 shares during the last quarter. Dimensional Fund Advisors LP lifted its holdings in Agile Therapeutics by 604.2% in the second quarter. Dimensional Fund Advisors LP now owns 95,820 shares of the specialty pharmaceutical company’s stock valued at $359,000 after acquiring an additional 82,213 shares during the last quarter. Goldman Sachs Group Inc. acquired a new position in Agile Therapeutics in the second quarter valued at approximately $309,000. Finally, LMR Partners LLP purchased a new stake in Agile Therapeutics in the second quarter valued at approximately $211,000. Hedge funds and other institutional investors own 67.59% of the company’s stock.

In other Agile Therapeutics news, Chairman Alfred Altomari acquired 10,000 shares of the firm’s stock in a transaction that occurred on Friday, August 25th. The shares were purchased at an average cost of $3.34 per share, for a total transaction of $33,400.00. Following the completion of the acquisition, the chairman now owns 161,587 shares of the company’s stock, valued at approximately $539,700.58. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Corporate insiders own 3.50% of the company’s stock.

Agile Therapeutics Company Profile

Agile Therapeutics, Inc is a women’s health specialty pharmaceutical company. The Company is focused in the development and commercialization of prescription contraceptive products. The Company has developed a transdermal patch technology, called Skinfusion. The Company’s lead product candidate is Twirla, also known as AG200-15, is a combined hormonal contraceptive (CHC) patch.

Earnings History and Estimates for Agile Therapeutics (NASDAQ:AGRX)

Receive News & Ratings for Agile Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agile Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply